Analysts Anticipate Aerpio Pharmaceuticals, Inc. (ARPO) to Announce -$0.22 Earnings Per Share

Brokerages predict that Aerpio Pharmaceuticals, Inc. (NYSE:ARPO) will report earnings of ($0.22) per share for the current quarter, Zacks reports. Zero analysts have issued estimates for Aerpio Pharmaceuticals’ earnings. Aerpio Pharmaceuticals reported earnings per share of ($0.27) during the same quarter last year, which indicates a positive year over year growth rate of 18.5%. The business is expected to report its next quarterly earnings results on Tuesday, May 21st.

On average, analysts expect that Aerpio Pharmaceuticals will report full year earnings of ($0.74) per share for the current fiscal year, with EPS estimates ranging from ($0.86) to ($0.61). Zacks Investment Research’s EPS calculations are an average based on a survey of analysts that follow Aerpio Pharmaceuticals.

ARPO has been the subject of several recent research reports. HC Wainwright downgraded shares of Aerpio Pharmaceuticals from a “buy” rating to a “neutral” rating in a research note on Tuesday, March 19th. Cantor Fitzgerald reiterated an “overweight” rating on shares of Aerpio Pharmaceuticals in a research note on Friday, January 18th.

ARPO opened at $1.00 on Monday. Aerpio Pharmaceuticals has a twelve month low of $0.88 and a twelve month high of $5.00.

Aerpio Pharmaceuticals Company Profile

Aerpio Pharmaceuticals, Inc, a biopharmaceutical company, focuses on developing and commercializing treatments for ocular diseases. The company's lead product candidate is AKB-9778, a small molecule activator of the Tie2 pathway, which completed the Phase 2a clinical trial for the treatment of diabetic retinopathy.

Read More: Current Ratio

Get a free copy of the Zacks research report on Aerpio Pharmaceuticals (ARPO)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Aerpio Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aerpio Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.